Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230954 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
A Phase 2 study, sponsored by University of South Alabama.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04230954: Clinical Trial Phase 2 study, sponsored by University of South Alabama.
NCT04230954 is a Phase 2 study that was terminated before completion, run by University of South Alabama. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230954, a Phase 2 study, was terminated before completion, sponsored by University of South Alabama.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Drug: Cabozantinib Drug: Pembrolizumab
Interventions
- DRUG Cabozantinib 40 MG oral once a day
- DRUG Pembrolizumab 200 mg IV every 3 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04230954
The ClinicalTrials.gov registry entry for NCT04230954 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Alabama, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabozantinib 40 MG oral once a day is the first listed.
NCT04230954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04230954 about?
NCT04230954 is a clinical study titled "Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer". Drug: Cabozantinib Drug: Pembrolizumab
What is the current status of trial NCT04230954?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-04-16. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT04230954?
The interventions under investigation include: Cabozantinib 40 MG oral once a day (DRUG), Pembrolizumab 200 mg IV every 3 weeks (DRUG).
Who is sponsoring clinical trial NCT04230954?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.